Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL 9: Once-weekly somapacitan in paediatric short stature syndromes
2022-501055-87-01Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3 trial of somapacitan in growth disorder, Noonan syndrome, Small for gestational age (SGA) and 2 more (4 cohorts), sponsored by Novo Nordisk. Primary endpoint: Number of adverse events (AEs) from week 0 to week 26. Planned start Mar 2023; status: authorised.
02
Drugs
somapacitan
03
Conditions
growth disorderNoonan syndromeSmall for gestational age (SGA)Idiopathic Short Stature (ISS)Turner syndrome (TS)
Beyond the preview
Go deeper on 2022-501055-87-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501055-87-01.